We have recently shown that there is significant regulation of Bcl-2 apoptotic inhibitors in ER+ breast cancer models in response to treatment with MDM2i and endocrine therapy, including upregulation of both Bcl-XL and Mcl-1 that may limit the potential of this treatment combination to induce apoptosis (29). The gene discussed is BCL2; the disease is breast carcinoma.